Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio and is available for RUO or GCP applications.
Highlights:
Q2 Solutions TMB levels trend with published TMB levels across different cancer types | |||||||
---|---|---|---|---|---|---|---|
LGG | CHOL | KIRC | COAD | BLCA | LUSC | SKCM | |
Q2 Solutions TMB (WES)1 |
1.5 (N=123) |
2.4 (N=38) |
2.4 (N=100) |
4.6 (N=64) |
8.7 (N=39) |
10.1 (N=258) |
13.2 (N=113) |
Published TMB2 | 1.8 (N=220) |
2.5 (N=1456) |
2.7 (N=543) |
4.5 (N=7758) |
7.2 (N=80) |
9 (N=2102) |
14.4 (N=879) |
1Median TMB scores generated from TCGA whole exome sequencing reads through our pipeline
2 Median TMB scores per Chalmers et al., Genome Medicine 2017
3 https://gdc.cancer.gov/about-data /publications/mc3-2017
LGG=Lower Grade Glioma, CHOL=Cholangiocarcinoma, KIRC=Renal Clear Cell Carcinoma, COAD=Colon Adenocarcinoma, BLCA=Urothelial Carcinoma, LUSC=Lung Squamous Cell Carcinoma,
SKCM=Cutaneous Melanoma, BRCA=Breast Invasive Carcinoma, HNSC=Head-Neck Squamous Cell Carcinoma, LUAD=Lung Adenocarcinoma, SKCM=Cutaneous Melanoma; STAD=Stomach Adenocarcinoma
TMB assay specifications | |
---|---|
Sample Types | Tumor tissue (FFPE, fresh frozen or DNA specimens) Normal tissue, optional (PBMC, whole blood or DNA |
DNA Requirements | 250 ng DNA |
Assay Method | Whole Exome Sequencing |
System Compatibility | NovaSeq 6000, HiSeq 2500 |
Assay Performance | >99.9% accuracy of variant calling for variants above 10% allelic frequency Quantitative precision ≤20% CV% across TMB range of 2-32 |
Deliverables | TMB score, FASTQ, BAM, annotated VCF files |
Measurement of minimal residual disease (MRD) is one of the best predictors of treatment outcome for leukemia, lymphoma and myeloma.Two approaches of specific interest due to the innovation they...
Author: Victor Weigman, Ph.D., Associate Director, Associate Director, Translational Genomics, Q2 SolutionsThe excitement surrounding immuno-oncology (I-O) is being driven by results seen in the...